Sign in

You're signed outSign in or to get full access.

Talya Nevo-Hacohen

About Talya Nevo-Hacohen

Talya Nevo-Hacohen (age 65) has served on Seritage Growth Properties’ Board since 2022 and is currently an independent trustee. She brings over three decades of real estate investment, capital markets, and REIT leadership experience and serves as EVP, Chief Investment Officer and Treasurer of Sabra Health Care REIT, Inc. (since 2010) . The Board has affirmatively determined her to be independent under NYSE rules .

Past Roles

OrganizationRoleTenureCommittees/Impact
Sabra Health Care REIT, Inc.EVP, Chief Investment Officer and Treasurer2010–presentSenior executive leadership in REIT investing/capital allocation
Private real estate advisoryAdvisor to developers/operators (acq/dispo, capital raising)Sep 2006–Aug 2008; Feb 2009–Nov 2010Transaction advisory and financing counsel
Cerberus Real Estate Capital Mgmt., LLCManaging DirectorPrior to 2009 (dates not specified)Real estate private equity leadership
Healthpeak Properties, Inc. (formerly HCP, Inc.)SVP – Capital Markets and Treasurer2003–2006REIT capital markets and treasury
Goldman SachsVice President (investment banking; finance/ops/admin)Prior 10 years (dates not specified)Investment banking and finance roles
Architectural firms (NY)ArchitectEarly careerBuilt environment background

External Roles

OrganizationRoleCapacity
South Coast RepertoryPresident, Board of TrusteesNon-profit board leadership
Yale University – Jackson School of Global AffairsBoard of AdvisorsAcademic advisory role
U.S. Friends of Dror IsraelChairman of the BoardNon-profit governance
ZnestAdvisory Board memberPrivate advisory role
Spike’s K9 FundBoard memberNon-profit board service

Board Governance

  • Committee assignments: Member – Audit Committee; Chair – Nominating & Corporate Governance Committee; not a member of Compensation or Investment Committees .
  • Committee activity (2024): Audit (7 meetings), Nominating & Corporate Governance (2), Compensation (0; handled administrative matters by correspondence; 2024 items addressed in 4Q23), Investment (acted by unanimous written consents) .
  • Independence: The Board determined Nevo-Hacohen is independent; all Audit members meet heightened independence criteria .
  • Attendance and engagement: In 2024 the Board held 4 regular and 1 special meeting; all current trustees serving during 2024 attended at least 75% of Board and committee meetings on which they served and attended the 2024 annual meeting .
  • Board leadership: Adam Metz serves as Chair and Interim CEO; Mitchell Sabshon is Lead Independent Trustee (as of April 2025). Independent trustees meet in executive session at least twice annually under governance guidelines .

Fixed Compensation (Director)

ComponentAmountNotes
Annual cash retainer (non-employee trustee)$150,000Paid quarterly
Committee chair retainer (each chair role)$15,000Applies to Audit, Compensation, N&CG, Investment
Chair of the Board retainer (if applicable)$50,000Chair-only increment (not applicable to Nevo-Hacohen)
2024 Fees Earned – Talya Nevo-Hacohen$165,000$150,000 base + $15,000 as N&CG Chair
Equity awards to trusteesNoneCompany states trustees were not awarded equity compensation

Performance Compensation (Director)

ElementStatusPerformance Metrics
Equity compensation (RSUs/PSUs/Options)None granted to trusteesN/A
Cash bonus tied to metricsNot applicable to trusteesN/A (director pay is retainer-based)

Other Directorships & Interlocks

CategoryDetail
Current public company directorshipsNone disclosed for Nevo-Hacohen in SRG’s proxy
Executive role at another public companyEVP, CIO & Treasurer, Sabra Health Care REIT, Inc. (public REIT)
Committee roles at other companiesNot disclosed
Potential interlocks/conflictsNone disclosed; Board reviewed independence and affirmed status . Related-party transactions disclosed involve ESL/Lampert and Winthrop/John Garilli, not Nevo-Hacohen .

Expertise & Qualifications

  • REIT investment and capital markets leadership as EVP/CIO/Treasurer of Sabra Health Care REIT .
  • Prior senior roles at Cerberus Real Estate and Healthpeak (Treasury/Capital Markets), with 10 years at Goldman Sachs (investment banking/finance) .
  • Architecture training and experience (useful for redevelopment and asset evaluation) .
  • Audit Committee member; Audit Committee financial expert designation resides with John T. McClain (chair) per Board determinations .

Equity Ownership

HolderClass A Shares Beneficially OwnedPercent of ClassNotes
Talya Nevo-Hacohen00%No Class A shares reported as of April 25, 2025
Hedging/pledging policy (trustees/officers)ProhibitedHedging and pledging of SRG securities is prohibited under insider trading policy
Director stock ownership guidelineCost at least equal to one annual retainer by 3rd anniversary of electionApplies to non-employee trustees; Nevo-Hacohen trustee since 2022

Watch item: As of April 25, 2025, no beneficial ownership is reported for Nevo-Hacohen. The Board’s guideline requires non-employee trustees to acquire shares with a cost at least equal to one annual retainer by the third anniversary of election (2025 for Nevo-Hacohen). Monitor for guideline compliance in subsequent disclosures .

Governance Assessment

  • Positives

    • Independence affirmed; serves on Audit and chairs Nominating & Corporate Governance—positions central to oversight of reporting, board composition, and governance practices .
    • Board and committee engagement: Audit (7) and N&CG (2) meetings in 2024; all trustees met the ≥75% attendance threshold and attended the annual meeting, indicating baseline engagement .
    • Strong conflict controls: Hedging/pledging prohibited for trustees/officers; Audit Committee must review/approve related-party transactions .
  • Concerns/Watch items

    • Alignment: Director compensation is entirely cash (no equity), and Nevo-Hacohen reported no share ownership as of April 25, 2025; pending visibility on compliance with the director ownership guideline by her third anniversary (2025) .
    • Compensation Committee inactivity in 2024 (0 meetings; used written actions and addressed 2024 matters in 4Q23) may draw scrutiny in a period of executive transitions, though permitted by governance norms; Nevo-Hacohen is not a member of that committee .
    • No disclosed individual attendance detail; only aggregate threshold met. Continued monitoring warranted as SRG executes its Plan of Sale .
  • Conflicts/Related-party exposure

    • No related-party transactions disclosed involving Nevo-Hacohen. SRG discloses related-party relationships with ESL/Lampert and Winthrop/John Garilli; independence determinations consider such relationships .